A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Imatinib in Patients With Gastro-Intestinal Stromal Tumour in First Line Medical Treatment

A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Imatinib in Patients With Gastro-Intestinal Stromal Tumour in First Line Medical Treatment

Gastrointestinal Stromal Tumor

Terminated

3

Start Date 01/31/2009

Age of Trial (yrs) 15.8

First-line

KIT/PDGFRA inhibitor

Block KIT

Specifically GIST and only GIST

AB04030

AB Science

Centre Oscar Lambret Antoine Adenis, M.D. a-adenis@o-lambret.fr +33 (0)3 20 29 59 59

Randomized

Oral

A Prospective, Multicenter, Randomized, Open-Label, Active-Controlled, 2-Parallel Group, Phase III Study to Compare Efficacy and Safety of Masitinib at 7.5 mg/kg/Day to Imatinib at 400 or 600 mg in Treatment of Patients With Gastro-Intestinal Stromal Tumour in First Line Medical Treatment